Abstract: Aspects of the present disclosure relate to a convective blanket that includes an air permeable upper sheet having a periphery. The convective blanket includes a lower sheet bonded to the upper sheet with a peripheral seal proximate to the periphery of the upper sheet to form an interior space therein between the upper and lower sheets. The convective blanket includes a wing portion partially surrounded by a portion of the peripheral seal and a body portion. Additional aspects relate to a system including the convective blanket and a method that uses the convective blanket.

Abstract: Aspects of the present disclose related to a system. The system includes a warming device having at least a first zone and a second zone and a sensor. The system also includes a controller that includes one or more processor circuits configured to receive a first sensor reading from the sensor corresponding to a first zone, wherein the first sensor reading corresponds to a first heat transfer rate. The one or more processor circuits are configured to determine whether the sensor reading is sufficient and increase a first heat transfer rate to a second heat transfer rate in the first zone in response to the sensor reading being insufficient.

Abstract: Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).

Abstract: A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient.

Abstract: A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient.

Abstract: Methods and kits for identifying neurological conditions in a patient by determining a level of expression of dynactin subunit p62 are disclosed. The neurological conditions may include, for example, Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA).